- Tafamidis for Cardiac Transthyretin Amyloidosis
-
Darae Kim, Jin-Oh Choi, Eun-Seok Jeon
-
Cardiovasc Prev Pharmacother. 2021;3(1):1-9. Published online January 31, 2021
-
DOI: https://doi.org/10.36011/cpp.2021.3.e1
-
-
45,477
View
-
130
Download
-
3
Citations
-
Abstract
PDF
- Transthyretin amyloid (ATTR) cardiomyopathy is a progressive disease caused by the infiltration of ATTR fibrils in the myocardium. Although it is a rare disease, ATTR cardiomyopathy is an important cause of heart failure with preserved ejection fraction, and its incidence is increasing due to improved diagnostic imaging tools. There has been a breakthrough in the field of transthyretin amyloidosis, which opens a new therapeutic door for the patients. In this review, an overview of tafamidis therapy in ATTR cardiomyopathy with recent results from clinical trials will be discussed.
-
Citations
Citations to this article as recorded by 
- Impact of Tafamidis on survival in elderly patients: Insights from the Healthcare European Amyloidosis Registry
Antoine Jobbé-Duval, Mounira Kharoubi, Erwan Donal, Fabrice Bauer, Amaury Broussier, Arnaud Bisson, Océane Bouchot, Phillipe Charron, Jérôme Costa, Pierre-Yves Courand, Charlotte Dagrenat, François Delelis, Jean-Christophe Eicher, Antoine Fraix, Barnabas International Journal of Cardiology.2025; 437: 133522. CrossRef - A Comprehensive Review on Chemistry and Biology of Tafamidis in
Transthyretin Amyloidosis
Monali B. Patil, Piyush Ghode, Prashant Joshi Mini-Reviews in Medicinal Chemistry.2024; 24(6): 571. CrossRef - Multimodal Imaging and Biomarkers in Cardiac Amyloidosis
Mi-Hyang Jung, Suyon Chang, Eun Ji Han, Jong-Chan Youn Diagnostics.2022; 12(3): 627. CrossRef
|